IRulya Therapeutics (IRLA) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Raymond James | Initiated Coverage | Outperform | $72.00 | Oct 9, 2026 |
| Rodman & Renshaw | Initiated Coverage | Buy | $70.00 | Sep 24, 2026 |
| Citizens | Upgraded | Market Perform → Market Outperform | $77.00 | Sep 22, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $70.00 | Aug 18, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $82.00 | Jul 29, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $4.00 | Jun 24, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $4.00 | Jun 23, 2026 |
| D. Boral Capital | Downgraded | Buy → Hold | — | Jan 30, 2026 |
| Citizens | Downgraded | Market Outperform → Market Perform | — | Jan 30, 2026 |
| D. Boral Capital | Maintained | Buy | $5.00 | Jan 29, 2026 |
| D. Boral Capital | Maintained | Buy | $5.00 from $4.00 | Dec 15, 2025 |
| D. Boral Capital | Maintained | Buy | $4.00 | Nov 13, 2025 |
| D. Boral Capital | Maintained | Buy | $4.00 | Sep 26, 2025 |
| D. Boral Capital | Maintained | Buy | $4.00 | Aug 15, 2025 |
| JMP Securities | Maintained | Market Outperform | $8.00 from $9.00 | Aug 12, 2025 |
| JMP Securities | Initiated Coverage | Market Outperform | $9.00 | Aug 5, 2025 |
| D. Boral Capital | Maintained | Buy | $4.00 | Jul 17, 2025 |
| D. Boral Capital | Maintained | Buy | $4.00 | Jun 13, 2025 |
| D. Boral Capital | Maintained | Buy | $4.00 | Jun 4, 2025 |
| D. Boral Capital | Maintained | Buy | $4.00 from $12.00 | Mar 25, 2025 |
Frequently asked questions
What is the price target for IRLA stock?
The average 12-month analyst price target for IRulya Therapeutics (IRLA) is $74.20, with a high estimate of $82.00 and a low of $70.00, across 5 analysts.
Is IRLA a buy, sell, or hold?
Analysts covering IRulya Therapeutics currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for IRLA?
The average price target of $74.20 implies 174.81% upside from the last price of $27.00.
What is the latest analyst rating on IRLA?
On Oct 9, 2026, Raymond James initiated coverage of IRulya Therapeutics at Outperform with a price target of $72.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.